WO2022158705A1 - 톡소포자충 단백질 및 인플루엔자 바이러스 단백질을 포함하는 바이러스 유사 입자 및 이를 이용한 진단 방법 - Google Patents
톡소포자충 단백질 및 인플루엔자 바이러스 단백질을 포함하는 바이러스 유사 입자 및 이를 이용한 진단 방법 Download PDFInfo
- Publication number
- WO2022158705A1 WO2022158705A1 PCT/KR2021/018383 KR2021018383W WO2022158705A1 WO 2022158705 A1 WO2022158705 A1 WO 2022158705A1 KR 2021018383 W KR2021018383 W KR 2021018383W WO 2022158705 A1 WO2022158705 A1 WO 2022158705A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- toxoplasmosis
- influenza virus
- vlps
- protein
- virus
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 47
- 239000002245 particle Substances 0.000 title claims abstract description 37
- 102000004169 proteins and genes Human genes 0.000 title abstract description 30
- 241000223997 Toxoplasma gondii Species 0.000 title abstract description 25
- 238000002405 diagnostic procedure Methods 0.000 title description 5
- 108700010900 influenza virus proteins Proteins 0.000 title description 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims abstract description 148
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 84
- 108091007433 antigens Proteins 0.000 claims abstract description 70
- 102000036639 antigens Human genes 0.000 claims abstract description 65
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 238000003745 diagnosis Methods 0.000 claims abstract description 32
- 239000012472 biological sample Substances 0.000 claims abstract description 8
- 101100523502 Arabidopsis thaliana ARAC5 gene Proteins 0.000 claims description 26
- 238000002965 ELISA Methods 0.000 claims description 26
- 101100523501 Oryza sativa subsp. japonica RAC4 gene Proteins 0.000 claims description 26
- 101100198869 Toxoplasma gondii ROP4 gene Proteins 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 23
- 101710199771 Matrix protein 1 Proteins 0.000 claims description 18
- 241000701447 unidentified baculovirus Species 0.000 claims description 12
- 238000009007 Diagnostic Kit Methods 0.000 claims description 11
- 230000009385 viral infection Effects 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000003119 immunoblot Methods 0.000 claims description 5
- 238000001262 western blot Methods 0.000 claims description 5
- 238000003149 assay kit Methods 0.000 claims description 4
- 238000011532 immunohistochemical staining Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000003322 Coinfection Diseases 0.000 claims description 2
- 238000010186 staining Methods 0.000 claims description 2
- 101150078331 ama-1 gene Proteins 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 abstract description 33
- 101000930553 Toxoplasma gondii (strain ATCC 50861 / VEG) Apical membrane antigen 1 Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 71
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- 239000000427 antigen Substances 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 230000005875 antibody response Effects 0.000 description 15
- 239000006166 lysate Substances 0.000 description 15
- 210000000059 tachyzoite Anatomy 0.000 description 15
- 206010022000 influenza Diseases 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000007865 diluting Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 208000031513 cyst Diseases 0.000 description 9
- 241000224021 Plasmodium berghei ANKA Species 0.000 description 8
- 241000387654 Toxoplasma gondii ME49 Species 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 201000004792 malaria Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 108060003393 Granulin Proteins 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 108010019400 Tla antigens Proteins 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 210000003250 oocyst Anatomy 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000008482 12E7 Antigen Human genes 0.000 description 2
- 108010020567 12E7 Antigen Proteins 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000255908 Manduca sexta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241000500439 Plutella Species 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 241000256248 Spodoptera Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000061 bradyzoite Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000001563 schizont Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WVAKRQOMAINQPU-UHFFFAOYSA-N 2-[4-[2-[5-(2,2-dimethylbutyl)-1h-imidazol-2-yl]ethyl]phenyl]pyridine Chemical compound N1C(CC(C)(C)CC)=CN=C1CCC1=CC=C(C=2N=CC=CC=2)C=C1 WVAKRQOMAINQPU-UHFFFAOYSA-N 0.000 description 1
- ALZUKTXGUHPTJD-UHFFFAOYSA-N 4-(4-amino-3,3-dinitrocyclohexa-1,5-dien-1-yl)-2,6-dinitroaniline Chemical compound [O-][N+](=O)C1([N+]([O-])=O)C(N)C=CC(C=2C=C(C(N)=C(C=2)[N+]([O-])=O)[N+]([O-])=O)=C1 ALZUKTXGUHPTJD-UHFFFAOYSA-N 0.000 description 1
- BOTGCZBEERTTDQ-UHFFFAOYSA-N 4-Methoxy-1-naphthol Chemical compound C1=CC=C2C(OC)=CC=C(O)C2=C1 BOTGCZBEERTTDQ-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 101710203310 Apical membrane antigen 1 Proteins 0.000 description 1
- 101100162403 Arabidopsis thaliana ALEU gene Proteins 0.000 description 1
- 101100355582 Arabidopsis thaliana ARAC1 gene Proteins 0.000 description 1
- 101100355576 Arabidopsis thaliana ARAC10 gene Proteins 0.000 description 1
- 101100355577 Arabidopsis thaliana ARAC11 gene Proteins 0.000 description 1
- 101100139843 Arabidopsis thaliana ARAC2 gene Proteins 0.000 description 1
- 101100523496 Arabidopsis thaliana ARAC3 gene Proteins 0.000 description 1
- 101100523500 Arabidopsis thaliana ARAC4 gene Proteins 0.000 description 1
- 101100523504 Arabidopsis thaliana ARAC6 gene Proteins 0.000 description 1
- 101100523506 Arabidopsis thaliana ARAC7 gene Proteins 0.000 description 1
- 101100523508 Arabidopsis thaliana ARAC8 gene Proteins 0.000 description 1
- 101100523509 Arabidopsis thaliana ARAC9 gene Proteins 0.000 description 1
- 102100037152 BAG family molecular chaperone regulator 1 Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 101100056797 Canis lupus familiaris SAG gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000567412 Estigmene acrea Species 0.000 description 1
- 101150010973 GRA1 gene Proteins 0.000 description 1
- 101150073248 GRA2 gene Proteins 0.000 description 1
- 241000256244 Heliothis virescens Species 0.000 description 1
- 101000740062 Homo sapiens BAG family molecular chaperone regulator 1 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101001018939 Homo sapiens MICOS complex subunit MIC10 Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241000721703 Lymantria dispar Species 0.000 description 1
- 101150109178 M1 gene Proteins 0.000 description 1
- 102100033551 MICOS complex subunit MIC10 Human genes 0.000 description 1
- 241000555303 Mamestra brassicae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 101100170542 Mus musculus Disp1 gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000409991 Mythimna separata Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 101100523507 Oryza sativa subsp. japonica RAC7 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101150041784 ROP4 gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 description 1
- 101100532512 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SAG1 gene Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000256247 Spodoptera exigua Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101100069381 Toxoplasma gondii GRA4 gene Proteins 0.000 description 1
- 101100069387 Toxoplasma gondii GRA7 gene Proteins 0.000 description 1
- 101100345585 Toxoplasma gondii MIC6 gene Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 210000000973 gametocyte Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000012092 latex agglutination test Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 108060006184 phycobiliprotein Proteins 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/45—Toxoplasma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
- G01N2333/45—Toxoplasma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Definitions
- the present invention provides a composition and kit for diagnosing Toxoplasmosis and / or influenza virus comprising virus-like particles comprising toxoplasmosis protein and influenza virus protein, and toxoplasmosis and / or influenza virus infection using the same. it's about how
- Toxoplasma gondii is an intracellular parasite that causes Toxoplasmosis in humans and animals (Astrid M. Tenter et al.). Toxoplasmosis is mainly oocyst (oocyst), vegetative (tachyzoit, tachyzoit), infectious (bradyzoit, bradyzoit), schizont (schizont) and reproductive matrix (gametocyte, arachnoid) There are five stages of development.
- Toxoplasma gondii is infected by ingesting water or vegetables contaminated by oocysts in cat feces, which are the definitive hosts, or feeds on Toxoplasmosis present as cysts in meat such as pigs, sheep, and cattle, which are intermediate hosts. can be infected when It is estimated that more than a third of the world's population is infected with Toxoplasmosis, and it is reported that the infection rate is 2 to 25% depending on the group in Korea.
- Toxoplasmosis when Toxoplasmosis infects a mother, its trophozoite can infect the fetus via the placenta. Infection with Toxoplasmosis can lead to miscarriage or stillbirth in the early fetus, and congenital anomalies such as visual impairment, hydrocephalus, and mental retardation in the mid-late fetus despite a normal delivery.
- Toxoplasmosis infecting healthy individuals can cause diseases such as lymphadenitis, retinal choroiditis, and encephalomyelitis by destroying immune system cells and reticuloendothelial cells. It can cause meningitis or retinal choroiditis.
- influenza is one of the major causes of human death due to respiratory viruses. Common symptoms include fever, sore throat, shortness of breath and muscle pain, among others. Influenza viruses during the flu season are highly contagious, infecting 10% to 20% of the world's population and causing 250,000 to 500,000 deaths annually. What these diseases have in common is that the symptoms of other diseases have similar symptoms. Therefore, to reduce confusion with other diseases, immunological methods such as latex agglutination test, enzyme-linked immunosorbent assay, enzyme-linked immunospecific assay, ELISA, nested PCR, real-time PCR and Various diagnostic methods such as the same DNA detection method are used.
- Non-Patent Document 1 Astrid M. Tenter et al., "Toxoplasma gondii: from animals to humans", Int J Parasitol. 2000 Nov; 30(12-13), 1217-1258
- the present inventors studied to develop a method capable of diagnosing Toxoplasmosis with high sensitivity as well as simultaneously diagnosing influenza virus, but also rapid and economical.
- a diagnostic method including a composition for diagnosing VLP type according to the present invention was completed by confirming that the diagnostic kit has superior immunological specificity and sensitivity compared to antigen lysate antigen and antigen protein.
- a surface antigen protein derived from Toxoplasmosis provides a composition for multiple diagnosis of toxoplasmosis and/or influenza virus comprising virus-like particles comprising influenza virus matrix protein 1 (M1).
- M1 influenza virus matrix protein 1
- a toxoplasmosis and/or influenza virus multiple diagnosis kit comprising the composition for multiple diagnosis of toxoplasmosis and/or influenza virus.
- a surface antigen protein derived from Toxoplasmosis and contacting a biological sample isolated from an individual with a composition for multiple diagnosis of toxoplasmosis and/or influenza virus comprising virus-like particles comprising influenza virus matrix protein 1; and detecting an antibody that binds to a virus-like particle; provides a method for providing information necessary for multiple diagnosis of Toxoplasmosis and/or influenza virus infection, including.
- the diagnostic composition comprising virus-like particles containing Toxoplasmosis antigen protein and influenza virus M1 protein according to the present invention can react with autoantibodies present in the serum of an individual infected with Toxoplasmosis with high specificity and sensitivity. In addition, it can react with autoantibodies present in individuals infected with influenza virus. Accordingly, the virus-like particles may be usefully used for diagnosing Toxoplasmosis and/or influenza virus.
- AMA1, ROP4 or ROP18 VLPs Virus-like particles
- rBV recombinant baculovirus
- FIG. 2 is a time series showing the in vivo test process for obtaining the infected serum from the mouse in one embodiment of the present specification.
- FIG. 3 is a schematic diagram showing a method for diagnosing using ELISA using the VLP prepared in an embodiment of the present specification.
- Figure 4 shows naive mouse serum, P. berghei ANKA (protozoal malaria) or T. gondii (toxoplasma gondii) ME49-infected mouse serum coated with TLA (RH Tachyzoite lysate antigen), AMA1-M1-VLPs and AMA1 protein, respectively.
- TLA RH Tachyzoite lysate antigen
- AMA1-M1-VLPs AMA1 protein
- FIG. 5 shows the sensitivity of AMA1-M1-VLPs to the infected serum by contacting the serum of mice infected with T. gondii ME49 to an immune plate coated with TLA, AMA1-M1-VLPs and AMA1 proteins, respectively.
- FIG. 6 shows the sensitivity of AMA1-M1-VLPs to infected sera by contacting human sera infected with T. gondii ME49 to an immune plate coated with TLA, AMA1-M1-VLPs and AMA1 proteins, respectively.
- Figure 7 shows the ROP4-M1-VLPs against infected sera by contacting naive mouse sera, P. berghei ANKA or T. gondii ME49-infected mouse sera with immune plates coated with TLA, ROP4-M1-VLPs and ROP4 proteins, respectively. specificity was confirmed.
- FIG. 8 shows the sensitivity of ROP4-M1-VLPs to infected sera by contacting T. gondii ME49-infected mouse sera with immune plates coated with TLA, ROP4-M1-VLPs and ROP4 proteins, respectively.
- FIG. 9 shows the sensitivity of ROP4-M1-VLPs to infected sera by contacting human sera infected with T. gondii ME49 to an immune plate coated with TLA, ROP4-M1-VLPs and ROP4 proteins, respectively.
- Figure 10 shows the ROP18-M1-VLPs against infected sera by contacting naive mouse sera, P. berghei ANKA or T. gondii ME49-infected mouse sera with TLA, ROP18-M1-VLPs and ROP18 protein-coated immunoplates, respectively. specificity was confirmed.
- FIG. 11 shows the sensitivity of ROP18-M1-VLPs to infected sera by contacting T. gondii ME49-infected mouse sera with immune plates coated with TLA, ROP18-M1-VLPs and ROP18 proteins, respectively.
- FIG. 12 shows the sensitivity of ROP18-M1-VLPs to infected sera by contacting human sera infected with T. gondii ME49 to an immune plate coated with TLA, ROP18-M1-VLPs and ROP18 protein, respectively.
- FIG. 13 shows Naive mouse sera, T. gondii ME49-infected mouse sera, and influenza M1 VLPs inoculated with 10 ⁇ g of TLA, AMA1-M1-VLPs, ROP4-M1-VLPs and ROP18-M1-VLPs coated immunoplates, respectively. It shows the results of contacting the serum of the mouse and the serum of the mouse inoculated with NA (neuraminidase) VLPs 10 ⁇ g, respectively. As a result, it was confirmed that multiple diagnosis of toxoplasmosis and influenza virus is possible with AMA1-M1-VLPs, ROP4-M1-VLPs and ROP18-M1-VLPs.
- One aspect of the present invention is a surface antigen protein derived from Toxoplasmosis; And it provides a composition for multiple diagnosis of toxoplasmosis and/or influenza virus, comprising a virus-like particle (VLP) comprising influenza virus matrix protein 1 (M1).
- VLP virus-like particle
- M1 influenza virus matrix protein 1
- the composition may be a composition for multiple diagnosis of toxoplasmosis and influenza virus at the same time.
- virus-like particle refers to a non-infectious viral subunit with or without a viral protein.
- the virus-like particle may be completely devoid of a DNA or RNA genome.
- the virus-like particle may be prepared by a genetic engineering method, and includes an influenza virus-derived matrix protein (M1) as a core protein.
- M1 influenza virus-derived matrix protein
- the virus-like particle of the present invention can be produced by a genetic engineering method without a separate causative agent, that is, Toxoplasmosis.
- influenza virus matrix protein 1 is a structural protein of the influenza virus, and a matrix protein that forms a coat inside the fat layer, which is the envelope of the influenza virus. it means.
- the influenza virus consists of subtypes designated A, B and C.
- the influenza virus is surrounded by a layer of matrix protein (M1) that acts as a linker between the core and the viral envelope, and the M1 protein can be widely used as a structural protein in the development of influenza virus-like particles.
- the virus-like particle of the present specification includes influenza virus matrix protein 1 (M1) as a structural protein, and in one embodiment, M1 may have the amino acid sequence of SEQ ID NO: 1.
- the M1 may be encoded by the nucleic acid sequence of SEQ ID NO: 5.
- the Toxoplasmosis-derived surface antigen protein may be used in the present invention without being particularly limited in its type as long as it is a protein capable of inducing immune activity against Toxoplasmosis.
- the surface antigen protein of the present specification is SAG1 (membrane-associated surface antigen), SAG2, GRA1 (secreted dense-granule protein), GRA2, GRA4, GRA7, MIC1 (Microneme protein), MIC2, MIC4 derived from Toxoplasmosis.
- the AMA1 may have the amino acid sequence of SEQ ID NO: 2.
- the ROP4 may have the amino acid sequence of SEQ ID NO: 3.
- the ROP18 may have the amino acid sequence of SEQ ID NO: 4.
- AMA1 may be encoded by the nucleic acid sequence of SEQ ID NO: 6
- ROP4 may be encoded by the nucleic acid sequence of SEQ ID NO: 7
- ROP18 may be encoded by the nucleic acid sequence of SEQ ID NO: 8.
- the antigen protein introduced to the surface of the virus-like particle has high antigenicity compared to the purely isolated recombinant protein, so it can form an effective neutralizing antibody, and it can be used as a composition for multiple diagnosis of toxoplasmosis and influenza virus. .
- the ratio of Toxoplasmosis-derived surface antigen protein and influenza virus matrix protein 1 may be present in a ratio of 5:1 to 1:5. It may also be present in a ratio of 3:1, 1:1 or 1:3. Preferably, the ratio may be 3:1.
- the virus-like particles may be prepared using a vector containing a gene encoding a surface antigen protein derived from Toxoplasmosis and a vector containing a gene encoding influenza virus matrix protein 1. Specifically, the virus-like particles co-infect a host cell with a recombinant baculovirus containing a gene encoding a surface antigen protein derived from Toxoplasmosis and a recombinant baculovirus containing a gene encoding influenza virus matrix protein 1 It may be manufactured by
- the host cell may be an insect cell.
- insect cell any cell developed or commercially available as a host system for gene expression may be used, for example, Spodoptera frugiperda insect cells SF21, SF9, Trichoplusia ni, anti Carsa gemmitalis, Bombyx mori, Estigmene acrea, Heliothis virescens, Leucania separata, Limantria dispa (Lymantria dispar), Malacasoma disstria (Mammestra brassicae), Manduca sexta (Manduca sexta), Plutella zylostella (Plutella zylostella), Stodoptera exigua ( Spodoptera exigua) and Spodoptera littorlis (Spodoptera littorlis) may be selected from the group consisting of, but is not limited thereto.
- SF9 cells were used.
- a recombinant baculovirus containing a gene encoding a surface antigen protein derived from Toxoplasmosis and a recombinant baculovirus containing a gene encoding an influenza virus matrix protein 1 were infected in a 3:1 ratio to produce virus-like particles can be produced.
- the Toxoplasmosis-derived surface antigen protein; and virus-like particles comprising influenza virus matrix protein 1 have very good specificity and sensitivity. Thus, it can be used to detect autoantibodies produced in individuals infected with Toxoplasmosis and/or influenza virus.
- the VLPs may be utilized to determine the presence of an anti-AMA1 antibody, an anti-ROP4 antibody, or an anti-ROP18 antibody produced in an individual upon infection with Toxoplasmosis.
- it can be utilized to determine the presence or absence of anti-M1 antibody produced in an individual upon infection with influenza virus.
- the VLPs can more efficiently diagnose whether toxoplasmosis and influenza virus infection in an individual infected with both toxoplasmosis and influenza virus simultaneously.
- the VLPs of the present invention exhibit a significant antigen-antibody reaction not only with the serum from Toxoplasmosis-infected mice, but also with the serum from mice infected with influenza virus. It was confirmed that it can be usefully used for multiple diagnosis of influenza virus at the same time.
- Another aspect of the present invention provides a multiple diagnostic kit for toxoplasmosis and/or influenza virus comprising the composition for diagnosing toxoplasmosis and/or influenza virus.
- the diagnostic kit includes: Toxoplasmosis-derived surface antigen protein; and virus-like particles comprising influenza virus matrix protein 1 (M1).
- the diagnostic kit may be a diagnostic kit used for multiplex diagnosis of toxoplasmosis and influenza virus at the same time.
- the composition for diagnosing toxoplasmosis and/or influenza virus, the toxoplasmosis-derived surface antigen protein, the influenza virus matrix protein, and the virus-like particle are as described above.
- AMA1-M1-VLPs which are VLPs expressing Toxoplasmosis AMA1 protein, ROP4-M1-VLPs which are VLPs expressing Toxoplasmosis ROP4 protein, and ROP18-M1-VLPs which are VLPs expressing Toxoplasmosis ROP18 protein are used. So you can make a kit. In this case, the VLPs may be present in the detection unit of the diagnostic kit.
- the term “detection unit” refers to a portion comprising a support on which a VLP composition containing a Toxoplasmosis surface antigen protein is immobilized, and at least one of an antibody against Toxoplasmosis and an antibody against influenza virus and the VLP composition is specific It means a place that reacts hostilely.
- Toxoplasmosis and/or influenza virus multiple diagnostic composition of the detection unit is coated on the support (eg, nitrocellulose membrane) of the detection unit using a dispensing device, and the biological sample isolated from the subject is contacted with the toxoplasmosis. Diagnosis may be performed or multiple diagnosis of toxoplasmosis and influenza virus may be performed.
- the diagnostic kit includes an ELISA (Enzyme-linked immunosorbent assay) kit, a RIA (Radioimmnoassay) kit, a Sandwich assay kit, a Western Blot kit, an Immunoblot assay kit and an immunohistochemical staining ( Immnohistochemical staining) may be at least one selected from the group consisting of kits, but is not limited thereto.
- the diagnostic kit detects the presence or absence of an IgG antibody, IgA or IgM antibody in a biological sample isolated from an individual to diagnose whether toxoplasmosis and influenza virus infection individually or simultaneously, and in the process, ELISA (Enzyme-linked immunosorbent assay), RIA (Radioimmnoassay), Sandwich assay, Western Blot, Immunoblot assay and immunohistochemical staining method selected from the group consisting of It may be performed including at least one, but is not limited thereto.
- Another aspect of the present invention is a surface antigen protein derived from Toxoplasmosis; and contacting a biological sample isolated from an individual with a composition for multiple diagnosis of toxoplasmosis and/or influenza virus comprising virus-like particles comprising influenza virus matrix protein 1; and detecting an antibody that binds to a virus-like particle; provides a method of providing information necessary for multiple diagnosis of Toxoplasmosis and/or influenza virus infection, including.
- the composition for diagnosing toxoplasmosis and/or influenza virus, the toxoplasmosis-derived surface antigen protein, the influenza virus matrix protein, and the virus-like particle are as described above.
- the term "biological sample isolated from a subject” is preferably a body fluid secreted outside the body, and includes blood, serum, plasma, urine, tears, saliva, milk, and the like, and more preferably the subject. It may be blood obtained from, but is not limited thereto.
- the subject may be a mammal such as a dog, a cat, or a human, preferably a human.
- the step of detecting the antibody binding to the virus-like particle is ELISA (Enzyme-linked immunosorbent assay), RIA (Radioimmnoassay), sandwich assay (Sandwich assay), Western blot (Western Blot), immunoblot analysis (Immunoblot assay) and It may include at least one selected from the group consisting of immunohistochemical staining.
- the method of detecting the antibody binding to the virus-like particle may be a method of detecting an antigen-antibody reactant or a labeling factor.
- a method known to those skilled in the art may be used depending on the type of the antigen-antibody reactant or labeling factor, and specifically, the naked eye, detection equipment, detection reagent, etc. may be used.
- a confocal laser scanner may be used as the detection equipment, and the detection reagent is a predetermined predetermined that enables the presence of an analyte to be tested to be externally identified through the naked eye or other instruments. It may include a labeled reagent, an auxiliary specific binding member, and/or a component of a signaling system. Labeled detection reagents are well known to those of ordinary skill in the art to which the present invention pertains.
- labels include catalysts, enzymes (eg, phosphatase, peroxidase, etc., and more specifically, basic phosphatase and mutton peroxidase used together in combination with an enzyme substrate), enzyme substrates (eg, For example, nitroblue tetrazolium, 3,5',5,5'-tetranitrobenzidine, 4-methoxy-1-naphthol, 4-chloro-1-naphthol, 5-bromo-4-chloro-3- Indolyl phosphate, dioxetane as a chemiluminescent enzyme substrate, and derivatives and analogs thereof), fluorescent compounds (eg, fluorescein, phycobiliprotein, rhodamine, and derivatives thereof) and analogs), chemiluminescent compounds, metal sols, dye sols, particulate latex, color indicators, color matter contained in liposomes, carbon sols and and non-metal sols such as selenium, but is not limited thereto.
- Another aspect of the present invention the steps of contacting the biological sample isolated from the subject to the composition for diagnosis of toxoplasmosis and / or influenza virus; and detecting an antibody that binds to a virus-like particle; provides a method for multiple diagnosis of Toxoplasmosis and/or influenza virus infection, including.
- Another aspect of the present invention is a surface antigen protein derived from Toxoplasmosis; and virus-like particles comprising influenza virus matrix protein 1 (M1) for diagnostic use of toxoplasmosis and/or influenza virus infection.
- the use may be a use for diagnosing toxoplasmosis or multiple diagnosis of toxoplasmosis and influenza virus at the same time.
- RNA was obtained from Toxoplasmosis RH samples. Thereafter, the extracted antigen RNA was subjected to RT-PCR to obtain cDNA derived from Toxoplasmosis. Thereafter, dsDNA was obtained based on the obtained cDNA.
- primers for amplifying AMA1, ROP4 and ROP18 were designed and ordered. Distilled water was added to a mixture of 0.25 ⁇ l of PCR enzyme TaKaRa Ex Taq TM , 5 ⁇ l of 10X Ex Taq buffer, 4 ⁇ l of dNTP mixture, 1 ⁇ l of template, 2 ⁇ l of forward primer, and 2 ⁇ l of reverse primer so that the total volume was 50 ⁇ l. Thereafter, PCR was performed for 30 to 40 cycles at 98° C. for 10 seconds, 55° C. for 30 seconds, and at 72° C. for 1 minute.
- a PCR amplification product obtained by diluting a DNA marker and a loading dye (6x) on an agarose gel was loaded onto the gel. Thereafter, the PCR amplification product was confirmed using UV light or the like. Then, the DNA encoding the antigen was extracted from the gel in which the desired gene was located.
- the gene of AMA1 used 5'-AAAGAATTCACCATGGGGCTCGTGGGCGTACA-3' (SEQ ID NO: 11) as a forward primer and 5'-TTACTCGAGCTAGTAATCCCCCTCGACCA-3' (SEQ ID NO: 12) as a reverse primer
- the ROP4 gene was 5' as a forward primer -AAAGCATGCACCATGGGGCACCCTACCTCTTT-3' (SEQ ID NO: 13) and 5'-TTAGGTACCTCACGTTTCCGGTGGTGGCAT-3' (SEQ ID NO: 14) were used as a reverse primer
- the gene of ROP18 was 5'-AAAGGATCCACCATGTTTTCGGTACAGCGGCC-3' (SEQ ID NO: 15) as a forward primer and 5'-TTATCTAGATTATTCTGTGTGGAGATGTTC-3' (SEQ ID NO: 16) was used as a reverse primer.
- DNAs of AMA1, ROP4 and ROP18 which are Toxoplasmosis antigens extracted in Preparation Example 1.2, were loaded into a TA vector. Thereafter, the TA vector loaded with the antigen gene was transformed into E. coli cells and then cultured. After culturing the transformed E. coli cells, genes encoding AMA1, ROP4 and ROP18 were obtained therefrom.
- the AMA1, ROP4 and ROP18 antigen genes obtained in Preparation Example 1.3 were loaded into pFast-Bac vectors, respectively.
- the pFast-Bac vector loaded with the antigen gene was transformed into DH10B cells. Transformed cells were cultured to obtain a large amount of pFast-Bac vector loaded with the antigen gene.
- the pFast-Bac vector loaded with DNA of AMA1, ROP4 and ROP18 was transfected into SF9 cells using cellfectin II (Invitrogen, USA).
- Recombinant baculovirus (rBV) expressing AMA1, ROP4 and ROP18 was prepared through the Bac-to-Bac expression system (Invitrogen) according to the manufacturer's manual.
- rBV expressing influenza virus M1 was prepared in the same manner as above. At this time, the gene of M1 was amplified through RT-PCR using forward primer 5'-AAAGGATCCACCATGAGTCTTCTAACCGAGGT-3' (SEQ ID NO: 9) and reverse primer 5'-TTACTCGAGTTACTCTAGCTCTATGTTGAC-3' (SEQ ID NO: 10).
- AMA1 rBV and M1 rBV prepared in Preparation Example 1 were co-infected with SF9 cells. At this time, the ratio of M1 rBV to AMA1 antigen rBV was 1:3 for infection. Thereafter, the infected SF9 cells were cultured, and harvesting was performed when the SF9 cell death rate reached 30% to 40%. Specifically, the cultured cells and the culture medium were centrifuged at 6,000 rpm for 30 minutes to collect the supernatant, and then pelleted by centrifugation at 30,000 rpm and 4°C for 30 minutes. VLPs were purified through a sucrose gradient.
- VLPs were resuspended in phosphate-buffered saline (PBS) until use.
- PBS phosphate-buffered saline
- the VLPs expressing the AMA1 antigen and the M1 antigen were named AMA1-M1-VLPs.
- An example of a process for preparing AMA1-M1-VLP is shown in FIG. 1A.
- Toxoplasma gondii (ME49 strain) was orally infected with 300 cyst/mouse (hd) to 7-week-old female BALB/c mice. Serum was obtained. An exemplary sequence for the in-vivo process is shown in FIG. 2 . In addition, after infecting the mice with the malaria parasite ( P. berghei ANKA) 0.5% (0.5 ⁇ 10 4 ), serum was collected from the infected mice.
- Example 1 In order to check whether the AMA1-M1-VLPs of the present invention obtained in Example 1 can actually diagnose Toxoplasmosis-infected individuals, AMA1-M1 using serum from Toxoplasmosis-infected mice and human patients - It was confirmed by ELISA whether the VLPs reacted with the Toxoplasmosis specific antibody in the serum (Experimental Examples 1.1 to 1.3).
- TLA Tachyzoite lysate antigen obtained in Example 1 were each coated on a 96-well immunoplate at a concentration of 4 ⁇ g/ml.
- the TLA refers to a lysate antigen of a tachyzoite state in the life cycle of Toxoplasmosis RH.
- ELISA was performed by diluting 14 mouse sera infected with P. berghei ANKA and 14 mouse sera infected with T. gondii (Toxoplasma gondii) ME49 300 cysts 100-fold ( FIG. 3 ). Serum from mice not infected with the parasite malaria or Toxoplasmosis was used as a control (Naive).
- TLA and AMA1 protein antigens did not respond to any sera.
- AMA1-M1-VLPs showed little reaction with naive sera and sera infected with protozoa, and showed high reactivity only with sera infected with Toxoplasmosis. It was confirmed that there is specificity between the IgG antibodies (FIG. 4).
- Example 1.1 in addition to confirming that AMA-M1-VLPs specifically bind to Toxoplasmosis specific IgG antibody, the serum containing the IgG antibody was treated at various concentrations to confirm the sensitivity of these reactions.
- the same experiment as Example 1.1 was performed.
- AMA1-M1-VLPs obtained in Example 1, AMA1 protein, and TLA (RH Tachyzoite lysate antigen) were coated on a 96-well immunoplate at a concentration of 4 ⁇ g/ml, respectively. Thereafter, ELISA was performed by diluting 14 T. gondii ME49 300 cysts-infected mouse serum 100-fold, 300-fold, and 900-fold, respectively ( FIG. 3 ). Serum from mice not infected with Toxoplasmosis was used as a control (Naive).
- AMA1-M1-VLPs showed the highest specificity to mouse serum containing Toxoplasmosis-specific IgG, and among them, it was confirmed that the sensitivity was highest to serum at a concentration 100-fold diluted. (FIG. 5).
- AMA1-M1-VLPs obtained in Example 1 AMA1 protein, and TLA (RH Tachyzoite lysate antigen) were coated on a 96-well immunoplate at a concentration of 4 ⁇ g/ml, respectively. Thereafter, ELISA was performed by diluting 10 sera of T. gondii -infected patients 100-fold, 300-fold, and 900-fold, respectively (FIG. 3). Serum from mice not infected with Toxoplasmosis was used as a control (Naive).
- AMA1-M1-VLPs showed the highest specificity to human serum containing Toxoplasmosis specific IgG, and among them, the highest sensitivity to serum diluted 100 times. was confirmed (FIG. 6).
- Example 2 in order to determine whether the ROP4-M1-VLPs of the present invention obtained in Example 2 can actually diagnose an individual infected with Toxoplasmosis, serum of mice and human patients infected with Toxoplasmosis. Using, it was confirmed through ELISA whether ROP4-M1-VLPs react with Toxoplasmosis specific antibody in serum (Experimental Examples 2.1 to 2.3).
- ROP4-M1-VLPs, ROP4 protein and RH Tachyzoite lysate antigen (TLA) obtained in Example 2 were coated on a 96-well immunoplate at a concentration of 4 ⁇ g/ml, respectively. Then, ELISA was performed by diluting 14 mouse sera infected with P. berghei ANKA and 14 mouse sera infected with T. gondii (Toxoplasma gondii) ME49 300 cysts 100-fold ( FIG. 3 ). Serum from mice not infected with the parasite malaria or Toxoplasmosis was used as a control (Naive).
- TLA and AMA1 protein antigens did not respond to any sera.
- ROP4-M1-VLPs showed little reaction with naive sera and sera infected with protozoa, and showed high reactivity only with sera infected with Toxoplasmosis. It was confirmed that there is specificity between the IgG antibodies (FIG. 7).
- Example 2.1 in addition to confirming that ROP4-M1-VLPs specifically bind to Toxoplasmosis specific IgG antibody, in order to confirm the sensitivity of these reactions, the serum containing the IgG antibody was treated at various concentrations.
- the same experiment as Example 2.1 was performed.
- ROP4-M1-VLPs, ROP4 protein and RH Tachyzoite lysate antigen (TLA) obtained in Example 2 were coated on a 96-well immunoplate at a concentration of 4 ⁇ g/ml, respectively. Thereafter, ELISA was performed by diluting 14 T. gondii ME49 300 cysts-infected mouse serum 100-fold, 300-fold, and 900-fold, respectively (FIG. 3). Serum from mice not infected with Toxoplasmosis was used as a control (Naive).
- ROP4-M1-VLPs showed the highest specificity to mouse serum containing Toxoplasmosis-specific IgG, and among them, it was confirmed that the highest sensitivity to a 100-fold diluted concentration ( Fig. 8).
- AMA1-M1-VLPs showed the highest specificity to human serum containing Toxoplasmosis specific IgG, and among them, the highest sensitivity to serum diluted 100 times. was confirmed (FIG. 9).
- Example 3 As in Experimental Example 1, in order to confirm whether the ROP18-M1-VLPs of the present invention obtained in Example 3 can actually diagnose an individual infected with Toxoplasmosis, serum of mice and human patients infected with Toxoplasmosis. Using, it was confirmed through ELISA whether ROP18-M1-VLPs react with Toxoplasmosis specific antibody in serum (Experimental Examples 3.1 to 3.3).
- ROP18-M1-VLPs, ROP18 protein and RH Tachyzoite lysate antigen (TLA) obtained in Example 3 were coated on a 96-well immunoplate at a concentration of 4 ⁇ g/ml, respectively. Then, ELISA was performed by diluting 14 mouse sera infected with P. berghei ANKA and 14 mouse sera infected with T. gondii (Toxoplasma gondii) ME49 300 cysts 100-fold ( FIG. 3 ). Serum from mice not infected with protozoan malaria or Toxoplasmosis was used as a control (naive).
- TLA and AMA1 protein antigens did not react to any sera.
- ROP18-M1-VLPs showed little reaction with naive sera and sera infected with protozoal malaria, and showed high reactivity only with sera infected with Toxoplasmosis. It was confirmed that there is specificity between the IgG antibodies (FIG. 10).
- Example 3.1 in addition to confirming that ROP18-M1-VLPs specifically bind to Toxoplasmosis specific IgG antibody, in order to confirm the sensitivity of these reactions, the serum containing the IgG antibody was treated at various concentrations.
- the same experiment as Example 3.1 was performed.
- ROP18-M1-VLPs, ROP18 protein and RH Tachyzoite lysate antigen (TLA) obtained in Example 3 were coated on a 96-well immunoplate at a concentration of 4 ⁇ g/ml, respectively. Thereafter, ELISA was performed by diluting 14 T. gondii ME49 300 cysts-infected mouse serum 100-fold, 300-fold, and 900-fold, respectively ( FIG. 3 ). Serum from mice not infected with Toxoplasmosis was used as a control (Naive).
- ROP18-M1-VLPs showed the highest specificity to mouse serum containing Toxoplasmosis specific IgG, and among them, it was confirmed that the highest sensitivity to serum diluted 100-fold. (FIG. 11).
- AMA1-M1-VLPs showed the highest specificity to human serum containing Toxoplasmosis-specific IgG, and among them, the highest sensitivity to serum diluted 100-fold. was confirmed (FIG. 12).
- AMA1-M1-VLPs, ROP4-M1-VLPs, ROP18-M1-VLPs and TLA RVT Tachyzoite lysate antigen obtained in Examples 1 to 3 were coated on a 96-well immunoplate at a concentration of 4 ⁇ g/ml, respectively. did.
- ELISA was performed by 100-fold dilution of naive mouse serum, T. gondii ME49 300 cysts-infected mouse serum, influenza M1 VLPs inoculated with 10 ⁇ g, and NA (neuraminidase) VLPs inoculated with 10 ⁇ g serum. proceeded.
- NA VLPs were prepared by amplifying the cDNA of NA in influenza virus A/PR/8/34 (H1N1), and preparing T. gondii VLPs by the same method.
- AMA1-M1-VLPs, ROP4-M1-VLPs and ROP18-M1-VLPs were coated with the AMA1-M1-VLPs, ROP4-M1-VLPs and ROP18-M1-VLPs-coated immunoplates by measuring a value of 0.2 or more for the serum of mice inoculated with influenza M1 VLPs or NA VLPs 10 ⁇ g at the same time. It was confirmed that multiple diagnosis of toxoplasmosis and influenza virus is possible (FIG. 13).
- AMA1-M1-VLPs, ROP4-M1-VLPs and ROP18-M1-VLPs were highly sensitive to anti-AMA1 antibodies, anti-ROP4 antibodies and/or anti-ROP18 antibodies present in the sera of Toxoplasmosis-infected individuals. It was confirmed that it can be detected not only with the specificity of the virus, but also with the anti-M1 antibody present in the serum of an individual infected with influenza virus or with high sensitivity and specificity.
- the AMA1-M1-VLPs, ROP4-M1-VLPs and ROP18-M1-VLPs of the present application may be used as a composition for simultaneously diagnosing an individual infected with Toxoplasmosis and/or an individual infected with an influenza virus.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (12)
- 톡소포자충 유래의 표면 항원 단백질; 및 인플루엔자 바이러스 매트릭스 단백질 1(M1)을 포함하는 바이러스-유사 입자를 포함하는 톡소포자충증 및/또는 인플루엔자 바이러스 다중 진단용 조성물.
- 제1항에 있어서,상기 톡소포자충 유래의 표면 항원 단백질은 AMA1, ROP4 및 ROP18로 구성된 군으로부터 선택된 적어도 하나인 것인, 톡소포자충증 및/또는 인플루엔자 바이러스 다중 진단용 조성물.
- 제1항에 있어서,상기 M1은 서열번호 1의 아미노산 서열을 가지는 것인, 톡소포자충증 및/또는 인플루엔자 바이러스 다중 진단용 조성물.
- 제2항에 있어서,상기 AMA1은 서열번호 2의 아미노산 서열을 가지며,상기 ROP4는 서열번호 3의 아미노산 서열을 가지며,상기 ROP18은 서열번호 4의 아미노산 서열을 가지는 것인, 톡소포자충증 및/또는 인플루엔자 바이러스 다중 진단용 조성물.
- 제1항에 있어서,바이러스-유사 입자에서 톡소포자충 유래의 표면 항원 단백질 및 인플루엔자 바이러스 매트릭스 단백질 1의 비율은 3:1인 것인, 톡소포자충증 및/또는 인플루엔자 바이러스 다중 진단용 조성물.
- 제1항에 있어서,상기 바이러스-유사 입자는 톡소포자충 유래의 표면 항원 단백질을 코딩하는 유전자를 포함하는 재조합 배큘로바이러스 및 인플루엔자 바이러스 매트릭스 단백질 1을 코딩하는 유전자를 포함하는 재조합 배큘로바이러스를 공동 감염시켜 제조된 것인, 톡소포자충증 및/또는 인플루엔자 바이러스 다중 진단용 조성물.
- 제5항에 있어서,공동 감염시에 톡소포자충 유래의 표면 항원 단백질을 코딩하는 유전자를 포함하는 재조합 배큘로바이러스와 인플루엔자 바이러스 매트릭스 단백질 1을 코딩하는 유전자를 포함하는 재조합 배큘로바이러는 3:1로 감염시키는 것을 특징으로 하는, 톡소포자충증 및/또는 인플루엔자 바이러스 다중 진단용 조성물.
- 제1항에 있어서,톡소포자충 및/또는 인플루엔자 바이러스의 감염된 개체의 자가 항체의 수준을 진단하는 것을 특징으로 하는, 톡소포자충증 및/또는 인플루엔자 바이러스 다중 진단용 조성물.
- 제1항 내지 제8항 중 어느 한 항의 조성물을 포함하는 톡소포자충 및/또는 인플루엔자 바이러스 다중 진단 키트.
- 제9항에 있어서,상기 진단 키트는 ELISA(Enzyme-linked immunosorbent assay) 키트, RIA(Radioimmnoassay) 키트, 샌드위치 측정법(Sandwich assay) 키트, 웨스턴 블롯(Western Blot) 키트, 면역블롯 분석(Immunoblot assay) 키트 및 면역조직화학염색(Immnohistochemical staining) 키트로 구성된 군으로부터 선택되는 어느 하나인 것인, 톡소포자충 및 인플루엔자 바이러스 다중 진단 키트.
- 톡소포자충 유래의 표면 항원 단백질; 및 인플루엔자 바이러스 매트릭스 단백질 1을 포함하는 바이러스-유사 입자를 포함하는 톡소포자충증 및/또는 인플루엔자 바이러스 다중 진단용 조성물에 개체로부터 분리된 생물학적 시료를 접촉시키는 단계; 및바이러스-유사 입자에 결합하는 항체를 검출하는 단계;를 포함하는 톡소포자충 및/또는 인플루엔자 바이러스의 감염을 다중 진단하기 위해 필요한 정보를 제공하는 방법.
- 제11항에 있어서,상기 톡소포자충 유래의 표면 항원 단백질은 AMA1, ROP4, ROP18로 구성된 군으로부터 선택된 어느 하나인 것인, 톡소포자충 및/또는 인플루엔자 바이러스의 감염을 다중 진단하기 위해 필요한 정보를 제공하는 방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023544409A JP2024509043A (ja) | 2021-01-22 | 2021-12-06 | トキソプラズマタンパク質およびインフルエンザウイルスタンパク質を含むウイルス様粒子およびこれを用いた診断方法 |
AU2021421855A AU2021421855A1 (en) | 2021-01-22 | 2021-12-06 | Virus-like particle comprising toxoplasma gondii protein and influenza virus protein, and diagnostic method using same |
EP21921464.0A EP4283296A1 (en) | 2021-01-22 | 2021-12-06 | Virus-like particle comprising toxoplasma gondii protein and influenza virus protein, and diagnostic method using same |
US18/262,327 US20240085420A1 (en) | 2021-01-22 | 2021-12-06 | Virus-like particle comprising toxoplasma gondii protein and influenza virus protein, and diagnostic method using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0009692 | 2021-01-22 | ||
KR1020210009692A KR102508574B1 (ko) | 2021-01-22 | 2021-01-22 | 톡소포자충 단백질 및 인플루엔자 바이러스 단백질을 포함하는 바이러스 유사 입자 및 이를 이용한 진단 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022158705A1 true WO2022158705A1 (ko) | 2022-07-28 |
Family
ID=82549514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/018383 WO2022158705A1 (ko) | 2021-01-22 | 2021-12-06 | 톡소포자충 단백질 및 인플루엔자 바이러스 단백질을 포함하는 바이러스 유사 입자 및 이를 이용한 진단 방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240085420A1 (ko) |
EP (1) | EP4283296A1 (ko) |
JP (1) | JP2024509043A (ko) |
KR (1) | KR102508574B1 (ko) |
AU (1) | AU2021421855A1 (ko) |
WO (1) | WO2022158705A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120018783A (ko) * | 2009-05-01 | 2012-03-05 | 레드바이오텍 아게 | 다중 유전자 벡터에 의해 암호화된 재조합 바이러스-유사 입자 |
KR20190005066A (ko) * | 2017-07-05 | 2019-01-15 | 경희대학교 산학협력단 | 톡소포자충 바이러스-유사입자, 이를 유효성분으로 포함하는 백신 조성물, 이를 제조하기 위한 벡터, 및 이의 제조 방법 |
KR102165100B1 (ko) * | 2019-09-27 | 2020-10-14 | 주식회사 헬스파크 | 톡소포자충 유래의 곤봉체 단백질을 발현하는 바이러스-유사 입자, 및 이를 포함하는 약학적 조성물 |
US20200397887A1 (en) * | 2015-06-25 | 2020-12-24 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (vlps) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101881014B1 (ko) * | 2016-04-15 | 2018-07-23 | 경희대학교 산학협력단 | 톡소포자충 바이러스-유사입자, 이를 제조하기 위한 벡터, 및 이의 제조 방법 |
-
2021
- 2021-01-22 KR KR1020210009692A patent/KR102508574B1/ko active IP Right Grant
- 2021-12-06 US US18/262,327 patent/US20240085420A1/en active Pending
- 2021-12-06 WO PCT/KR2021/018383 patent/WO2022158705A1/ko active Application Filing
- 2021-12-06 EP EP21921464.0A patent/EP4283296A1/en active Pending
- 2021-12-06 JP JP2023544409A patent/JP2024509043A/ja active Pending
- 2021-12-06 AU AU2021421855A patent/AU2021421855A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120018783A (ko) * | 2009-05-01 | 2012-03-05 | 레드바이오텍 아게 | 다중 유전자 벡터에 의해 암호화된 재조합 바이러스-유사 입자 |
US20200397887A1 (en) * | 2015-06-25 | 2020-12-24 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (vlps) |
KR20190005066A (ko) * | 2017-07-05 | 2019-01-15 | 경희대학교 산학협력단 | 톡소포자충 바이러스-유사입자, 이를 유효성분으로 포함하는 백신 조성물, 이를 제조하기 위한 벡터, 및 이의 제조 방법 |
KR102165100B1 (ko) * | 2019-09-27 | 2020-10-14 | 주식회사 헬스파크 | 톡소포자충 유래의 곤봉체 단백질을 발현하는 바이러스-유사 입자, 및 이를 포함하는 약학적 조성물 |
Non-Patent Citations (2)
Title |
---|
ASTRID M. TENTER ET AL.: "Toxoplasma gondii: from animals to humans", INT J PARASITOL, vol. 30, pages 1217 - 1258 |
LEE SU-HWA, LEE DONG-HUN, PIAO YING, MOON EUN-KYUNG, QUAN FU-SHI: "Influenza M1 Virus-Like Particles Consisting of Toxoplasma gondii Rhoptry Protein 4", KOREAN JOURNAL OF PARASITOLOGY., SEOUL., KR, vol. 55, no. 2, 1 April 2017 (2017-04-01), KR , pages 143 - 148, XP055952703, ISSN: 0023-4001, DOI: 10.3347/kjp.2017.55.2.143 * |
Also Published As
Publication number | Publication date |
---|---|
JP2024509043A (ja) | 2024-02-29 |
KR102508574B1 (ko) | 2023-03-10 |
EP4283296A1 (en) | 2023-11-29 |
KR20220106589A (ko) | 2022-07-29 |
US20240085420A1 (en) | 2024-03-14 |
AU2021421855A1 (en) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015053455A1 (ko) | 중증열성혈소판감소증후군 바이러스 및 이를 이용한 sfts 진단 방법 및 키트 | |
FUKUMOTO et al. | Development of a polymerase chain reaction method for diagnosing Babesia gibsoni infection in dogs | |
da Silva et al. | Diagnosis of human visceral leishmaniasis by PCR using blood samples spotted on filter paper | |
Munch et al. | The significance of Epstein—Barr virus seropositivity in multiple sclerosis patients? | |
Guan et al. | The development and evaluation of a loop-mediated isothermal amplification (LAMP) method for detection of Babesia spp. infective to sheep and goats in China | |
CN110568178B (zh) | 一种寨卡病毒ns1抗原及其在制备荧光免疫层析试剂中的应用 | |
Zoth et al. | Multiple recombinant ELISA for the detection of bovine viral diarrhoea virus antibodies in cattle sera | |
CA3185631A1 (en) | Kits and methods for the enrichment and detection of rna viruses of the coronaviridae family | |
Lopez et al. | High-throughput identification of T-lymphocyte antigens from Anaplasma marginale expressed using in vitro transcription and translation | |
Seitzer et al. | From molecule to diagnostic tool: Theileria annulata surface protein TaSP | |
WO2021221493A1 (ko) | 사스 코로나바이러스 2 스파이크 단백질과 결합하는 수용체와 항체를 포함하는 사스 코로나바이러스 2 진단 키트 | |
WO2022158705A1 (ko) | 톡소포자충 단백질 및 인플루엔자 바이러스 단백질을 포함하는 바이러스 유사 입자 및 이를 이용한 진단 방법 | |
KR101317417B1 (ko) | 돼지열병바이러스의 탐지용 항원, 이를 이용한 항체 검출 방법, 및 이를 포함하는 탐지키트 | |
WO2017095135A1 (ko) | 쯔쯔가무시병 조기진단을 위한 igm, igg 항체 검출 진단키트 및 이의 제조방법 | |
Manosroi et al. | Early diagnosis of scrub typhus in Thailand from clinical specimens by nested polymerase chain reaction | |
Chomel et al. | Comparison between three rapid methods for direct diagnosis of influenza and the conventional isolation procedure | |
WO2018124659A1 (ko) | 서울바이러스와 푸말라바이러스 유래의 재조합 뉴클레오캡시드 단백질 및 한탄바이러스 유래의 재조합 당단백질을 포함하는 신증후군출혈열 진단용 조성물 및 이를 포함하는 진단 키트 | |
US9658227B2 (en) | Recombinant GRA antigens and the use of same for early diagnosis of toxoplasmosis | |
WO2020174690A1 (ja) | バベシア原虫の表面抗原タンパク質、バベシア原虫に対する抗体の検出方法、バベシア症の診断方法 | |
WO2020027617A1 (ko) | 쯔쯔가무시균 유래 외막 소포체를 이용한 쯔쯔가무시병의 진단방법 | |
Takakura et al. | Establishment of an enzyme-linked immunosorbent assay for detection of hantavirus antibody of rats using a recombinant of nucleocapsid protein expressed in Escherichia coli | |
JPH11346768A (ja) | イヌジステンパーウイルスヌクレオカプシド蛋白質の抗原性を有する蛋白質及び抗イヌジステンパーウイルスヌクレオカプシド蛋白質抗体測定試薬 | |
Reck et al. | Evaluation of buffered Trypanosoma evansi antigen and rapid serum agglutination test (BA/Te) for the detection of anti-T. evansi antibodies in horses in Brazil | |
KR102622780B1 (ko) | 톡소포자충 정점막 항원 1을 포함하는 바이러스-유사입자의 톡소포자충증 혈청 진단 용도 | |
WO2022196849A1 (ko) | 아프리카 돼지 열병 바이러스 감염 진단을 위한 항원 단백질 조성물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21921464 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18262327 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023544409 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021421855 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021921464 Country of ref document: EP Effective date: 20230822 |
|
ENP | Entry into the national phase |
Ref document number: 2021421855 Country of ref document: AU Date of ref document: 20211206 Kind code of ref document: A |